Advertisement

Trigger Point Injections for Pelvic Pain

Chapter

Abstract

Chronic pelvic pain is one of the most challenging problems gynecologists encounter in clinical practice. Although management often involves a combination of medical, physical, cognitive, and behavioral therapies, trigger point injections offer an additional option for treatment in a subset of patients. This office-based procedure has been used to improve pain associated with vaginismus, levator ani hypertonicity, vulvodynia, pudendal and ilioinguinal/iliohypogastric neuralgia. In this textbook chapter we review various injections used to treat pelvic pain, summarize the evidence for their use, and describe their role in treatment.

Keywords

Botulinum Toxin Trigger Point Pudendal Nerve Chronic Pelvic Pain Anterior Superior Iliac Spine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87:321–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol. 1996;87:55–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Ling FW, Slocumb JC. Use of trigger point injections in chronic pelvic pain. Obstet Gynecol Clin North Am. 1993;20(4):809–15.PubMedGoogle Scholar
  4. 4.
    Langford CF, Udvari NS, Ghoniem GM. Levator ani trigger point injections: an underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26(1):59–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Moldwin RM, Fariello JY. Myofascial trigger points of the pelvic floor: associations with urological pain syndromes and treatment strategies including injection therapy. Curr Urol Rep. 2013;14(5):409–17. doi: 10.1007/s11934-013-0360-7.PubMedCrossRefGoogle Scholar
  6. 6.
    Abbott JA. The use of botulinum toxin in the pelvic floor for women with chronic pelvic pain—a new answer to old problems? J Minim Invasive Gynecol. 2009;16(2):130–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract Neurol. 2008;4(12):676–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Cui K, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Criscuolo CM. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep. 2001;5:407–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaille TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44:46–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest. 2004;58:164–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A. Botulinum neurotoxin type a injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol. 2009;114(5):1008–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women. Obstet Gynecol. 2006;108(4):915–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Park AJ, Paraiso MFR. Successful use of botulinum toxin type A in the treatment of refractory postoperative dyspareunia. Obstet Gynecol. 2009;114:484–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Abbott J. Gynecological indications for the use of botulinum toxin in women with chronic pelvic pain. Toxicon. 2009;54:647–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Allergan, Inc 2013. Highlights of prescribing information. Accessed from: http://www.allergan.com/assets/pdf/botox_pi.pdf
  17. 17.
    The American College of Obstetricians and Gynecologists. Practice bulletin #119: Female sexual dysfunction. 2011. http://www.acog.org/Resources-And-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Female-Sexual-Dysfunction
  18. 18.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed (Text rev). Washington, DC: APA; 2000.Google Scholar
  19. 19.
    Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med. 2006;51(6):467–70.PubMedGoogle Scholar
  20. 20.
    Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res. 2007;19:84–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A—a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double-blinded study. J Sex Med. 2009;6(9):2523–37.PubMedCrossRefGoogle Scholar
  22. 22.
    Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32:213–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104:922–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Fortuna R, Vaz MA, Youssef AR, Longino D, Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin. J Biomech. 2011;44:39–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Nesbitt-Haws EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type A—single vs. repeat injections. Toxicon. 2013;63:83–7.CrossRefGoogle Scholar
  26. 26.
    Benson JT, Griffis K. Pudendal neuralgia, a severe pain syndrome. Am J Obstet Gynecol. 2005;192:1663–8.PubMedCrossRefGoogle Scholar
  27. 27.
    McDonald JS, Spigos DG. Computed tomography-guided pudendal block for treatment of pelvic pain due to pudendal neuropathy. Obstet Gynecol. 2000;95:306–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Hough DM, Wittenberg KH, Pawline W, Mause TP, King BF, Vrtiska TJ, Farrell MA, Antolak SJ. Chronic perineal pain caused by pudendal nerve entrapment: anatomy and CT-guided perineural injection technique. AJR Am J Roentgenol. 2003;181(2):561–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Peng PW, Tumber PS. Ultrasound-guided interventional procedures for patients with chronic pelvic pain—a description of techniques and review of the literature. Pain Physician. 2008;11(2):214–24.Google Scholar
  30. 30.
    Whiteside JL, Barber MD, Walters MD, Falcone T. Anatomy of ilioinguinal and iliohypogastric nerves in relation to trocar placement and low transverse incisions. Am J Obstet Gynecol. 2003;189:1574–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Bell EA, Jones BP, Olufolabi AJ, Dexter F, Phillips-Bute B, Greengass RA, Penning DH, Reynolds JD. Iliohypogastric-ilioinguinal peripheral nerve block for post-cesarean delivery analgesia decreases morphine use but not opioid-related side effects. Can J Anaesth. 2002;49(7):694–700.PubMedCrossRefGoogle Scholar
  32. 32.
    Wehbe SA, Ghulmiyyah LM, Dominique EH, Hosford SL, Ehleben CM, Saltzman SL, Sills ES. Prospective randomized trial of iliohypogastric-ilioinguinal nerve block on post-operative morphine use after inpatient surgery of the female reproductive tract. J Negat Results Biomed. 2008;7:11. doi: 10.1186/1477-5751-7-11.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Section of Female Pelvic Medicine and Reconstructive SurgeryMedStar Washington Hospital Center/Georgetown University School of MedicineWashington, DCUSA

Personalised recommendations